



FOR IMMEDIATE RELEASE

11 February 2009

**OGT OFFERS NEW GENOMIC DNA LABELLING KIT FOR
CYTOGENETICS ARRAYS**

Oxford, February 11, 2009 - Oxford Gene Technology (OGT), the pioneer of microarray-based technologies, has launched a Genomic DNA labelling kit offering a fast and simple protocol. The labelling kit, which is fully optimised for OGT's CytoSure™ family of high resolution oligonucleotide arrays, adds to the Company's comprehensive portfolio of products and services, which together provide a complete solution for cytogeneticists, from sample to result.

The Genomic DNA labelling kit contains Cy3 and Cy5 dyes for dual-colour hybridisations, and uses a unique buffer formulation to allow more efficient use of reagents without loss of signal intensity. The kit contains everything required for the protocol, including nucleotide mix, random primers, enzymes and even the clean-up columns and collection tubes. OGT also offers analysis software to allow easier interpretation of results with data exchange for comprehensive, state-of-the-art cytogenetic profiling, and comprehensive training for customers of its CytoSure arrays.

Barbara DuPont, Director of the Cytogenetics Laboratory at the Greenwood Genetic Center in South Carolina, USA, which provides diagnostic and clinical genetics services, said: "We have moved from the BAC platform to using OGT's CytoSure arrays, and it was a very easy transition. The array protocols are very quick and simple, and we get a lot of extra information with CytoSure. The addition of the labelling kit has further streamlined sample throughput."

Spencer Howell, Director of Cytogenetics at OGT, said: "I am delighted to announce the Genomic DNA labelling kit to accompany the second generation of CytoSure oligonucleotide arrays. By supplying arrays, reagents and analysis software, and with new products and array designs in development, we continue our commitment to providing aCGH analysis to cytogenetics laboratories around the world."

more...

For research use only

This product is provided under an agreement between Agilent Technologies, Inc. and OGT. The manufacture, use, sale or import of this product may be subject to one or more of U.S. patents, pending applications, and corresponding international equivalents, owned by Agilent Technologies, Inc. The purchaser has the non-transferable right to use and consume the product for RESEARCH USE ONLY AND NOT for DIAGNOSTICS PROCEDURES. It is not intended for use, and should not be used, for the diagnosis, prevention, monitoring, treatment or alleviation of any disease or condition, or for the investigation of any physiological process, in any identifiable human, or for any other medical purpose.

For further information, please contact:

Oxford Gene Technology, Begbroke Science Park,
Sandy Lane, Yarnton, Oxford OX5 1PF
Tel: +44 1865 856828; Fax: +44 1865 848684
W: www.ogt.co.uk; Email: products@ogt.co.uk

Editorial contact for further information or follow-up:

Sarah Withington at **kdm communications limited**, Bedford, UK
Tel. +44 (0) 1234 210555; Fax: +44 (0) 1234 342397
Email: ideas@kdm-communications.com

Notes to editors

About Oxford Gene Technology

Founded in 1995 by the pioneer of Southern Blotting and microarray technologies, Professor Sir Edwin Southern, OGT is based near Oxford, UK.

The key focus areas of OGT include:

1. **High Throughput Microarray Services. With a processing capacity of over 1,000 samples per week,** applications available include aCGH, CNV, methylation studies and miRNA.
2. **Cytogenetics products and services** for high resolution detection of chromosomal abnormalities. OGT offers a range of high resolution oligonucleotide arrays, labelling kits and analysis software that together provide a unique, comprehensive solution for cytogenetics.
 - CytoSure Syndrome Plus v2 array covers over 200 known cytogenetic syndrome regions and offers extensive coverage of the whole genome.
 - CytoSure Chromosome X High Density array targets genes on the X chromosome, including exons, miRNAs, rRNAs and snRNAs.
 - CytoSure analysis software offers easier result interpretation with a new optimised automated aberration detection capability, annotation with important areas of the genome (e.g. syndromes, genes, exons, etc.) and easy data exchange with links to publicly available databases
3. **Digital microarrays/ Single Cell analysis.** OGT's innovative, patent-protected technology development programme is aimed at analysing genomic events at the single cell level for major applications such as

stem cell and cancer biology.

- 4. Licensing.** OGT operates an open licensing policy which has successfully provided access for a number of companies to OGT's fundamental intellectual property, particularly in the area of microarrays.

For further information on OGT products and services please visit <http://www.ogt.co.uk/>

- ENDS -